Bisphosphonates for Secondary Prevention of Osteoporotic Fractures: A Bayesian Network Meta-Analysis of Randomized Controlled Trials
Table 1
Baseline characteristics of the trials included in the present study.
Study
Design
Mean age, (t1/t2) yrs
Interventions
No (t1/ t2)
Study duration
Outcome
Risk of bias
t1
t2
Allocation concealment
Blinding (patients/outcome assessors)
Incomplete outcome data
Nakamura et al., 2016
RCT
74/74
Zoledronate (5 mg/yr )
Placebo
301/296
2 yrs
1, 2, 3
Unclear
Low/Low
High
Wang et al., 2016
RCT
67.3/68.5
Alendronate (70 mg/w 2 yrs)
Placebo
37/37
2 yrs
1
Unclear
Low/Unclear
Low
Ji et al., 2013
RCT
67.3/65.5
Alendronate (70 mg/w 2 yrs)
Placebo
40/40
2 yrs
1, 2, 3
Unclear
Low/Unclear
Low
Nakamura et al., 2013
RCT
72.2/72.9/73
Ibandronate (1 mg/m) vs (0.5 mg/m)
Risedronate (2.5 mg/d)
382/376/376
3 yrs
1
Unclear
Low/Low
High
Recker et al., 2004
RCT
67/67
Ibandronate (1 mg/3 ms) vs (0.5 mg/3 ms)
Placebo
1912/975
3 yrs
1, 2, 3
Unclear
Low/Low
High
Chesnut et al., 2004
RCT
69/69
Ibandronate (2.5 mg/d) vs (20 mg/qod intermittent)
Placebo
977/975
3 yrs
1, 2, 3
Unclear
Low/Low
Low
Kushida et al., 2004
RCT
71.2/72.6
Alendronate (5 mg/d 3 yrs)
Placebo
90/80
3 yrs
1
Unclear
Low/Low
Low
Reginster et al., 2000
RCT
71/71
Risedronate (5 mg/d)
Placebo
408/408
3 yrs
1, 2, 3
Unclear
Low/Unclear
High
Harris et al., 1999
RCT
66/66
Risedronate (5 mg/d)
Placebo
821/820
3 yrs
1, 2, 3
Low
Low/Low
High
Clemmesen et al., 1997
RCT
67/68/70
Risedronate (2.5 mg/d) vs (2.5 mg/d, cyclic)
Placebo
44/44
3 yrs
1
Unclear
Low/Unclear
Unclear
Black et al., 1996
RCT
71/71
Alendronate (5 mg/d 2 yrs, 10 mg/d 1 yr)
Placebo
1022/1005
3 yrs
1, 2, 3
Unclear
Low/Low
High
Watts et al., 1990
RCT
64.7/65.7
Etidronate (400 mg/d, intermittent)
Placebo
105/104
2 yrs
1,2,3
Unclear
Low/Low
High
Storm et al., 1990
RCT
68.3/68.3
Etidronate (400 mg/d, intermittent)
Placebo
33/33
150 weeks
1, 2, 3
Unclear
Low/Unclear
Low
RCT: Randomized controlled trials; No: patients’ number; t1: treatment group; t2: control group; yrs: Years; d: daily; w: week; m: month; qod: every other day.Outcome (1) New vertebral fractures out of total subjects; (2) New hip fractures out of total subjects; (3) New nonvertebral nonhip fractures out of total subjects.
